Связь антиаритмической эффективности амиодарона с действием препарата на функцию щитовидной железы у больных с нарушениями ритма сердца
Диссертация
Коррекция дисфункций щитовидной железы (гипотиреоза и тиреотоксикоза) позволяет достичь нормализация тиреоидного статуса и продолжить эффективное лечение амиодароном у 96% пациентов. б. У больных с амиодарон-ассоциированным гипотиреозом обнаруживаются повышенные уровни общего холестерина, липопротеидов низкой плотности и триглицеридов сыворотки крови. Проведение заместительной терапии… Читать ещё >
Список литературы
- Голицын С.П., Соколов С. Ф. Внутрисердечное электрофизиологическое исследование в диагностике и лечении нарушений ритма и проводимости сердца. Методические рекомендации МЗ СССР 1993 г.
- Дедов И.И., Свириденко Н. Ю. Стратегия ликвидации йод-дефицитных заболеваний в РФ. Проблемы эндокринологии 2001 -47:6:1−10
- Фадеев В.В., Левченко И. А. Субклинический гипотиреоз. Проблемы эндокринологии 2002−2
- Aanderaud S., Sundsljord J., Aarbokke J. Amiodarone inhibits the conversion of thyroxine to triiodothyronine in isolated rat hepatocytes. Endocrinology 1984−115:1605−1608
- Albert S.G., Alves L.E., Rose E.P. Thyroid dysfunction during chronic amiodarone therapy. J Am Coll Cardiol 1987−9:175−183
- Althaus B.U., Staub J.J., Ryff De Leche A. LDL/HDL-changes in subclinical hypothyroidism: possible risk factors for coronary heart disease. Clin Endocrinol Oxf 1988- 28, 2: 157−163.
- Andreasen P., Agrback H., Bjerregaard P Pharmacokinetics of amiodarone after intravenous and oral administration. Eur J Clin Pharmacol 1981- 19: 293−299
- Arem R, Escalante DA, Arem N. Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein (a). Metabolism 1995- 44:1559−1563
- Arem R, Patsch W. Lipoprotein and apolipoprotein levels in subclinical hypothyroidism. Effect of levothyroxine therapy. Arch Intern Med 1990- 150:2097−2100
- Arem R., Escalante D.A., Arem N. Effect of L-thyroxine therapy on lipoprotein fractions in overt and subclinical hypothyroidism, with special reference to lipoprotein (a). Metabolism 1995,44:1559
- Bargout R, Jankov A, Dincer E. Amiodarone induces apoptosis of human and rat alveolar epithelial cells in vitro. Am J Physiol Lung Cell Mol Physiol. 2000- 278(5): 1039−44.
- Bartalena L, Brogioni S, Grasso L. Increased serum interleukin-6 concentration in patients with subacute thyroiditis: relationship with concomitant changes in serum T4-binding globulin concentration. J Endocrinol Invest 1993- 16:213−218
- Bartalena L, Grasso L, Brogioni S. Serum interleukin-6 in amiodarone-induced thyrotoxicosis. J Clin Endocrinol Metab 1994- 78:423−427
- Bartalena L., Brogioni S., Grasso L. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. J Clin Endocrinol Metab 1996- 81: 29 302 933.
- Bastenie P.A., Vanhaelst B.L., Neve P. Coronary heart disease in hypothyroidism. Observations in preclinical myxoedema. Lancet 1967- 2: 1221−1222.
- Beddows S.A. Page S.R., Taylor A.H. Cytotoxic effects of amiodarone and desethylamiodarone on human thyrocytes. Biochem Pharmacol 1989−38:4397−4403
- Binah, О., I. Rubinstein, E. Gilat. Effects of thyroid hormone on the action potential and membrane currents of guinea pig ventricular myocytes. Pflilgers Arch. 1987- 409: 214−216.
- Bindels A. J., Westendorp R.G., Frolich M. The prevalence of subclinical hypothyroidism at different total plasma cholesterol levels in middle aged men and women: a need for case-finding? Clin Endocrinol 1999- 50: 217−220
- Binz K., Burger A. Amiodarone and the thyroid function clinical implications Schweiz Med Wachenschr 1998- 128(26):1051−8
- Blossey HC, Peitsch W. Indication for subtotal thyroidectomy in patients with amiodarone-(iodine-)related hyperthyroidism. Wiener Med Wochenschr 1988- 18: 444−447
- Bogazzi F, Bartalena L, Brogioni S. Desethylamiodarone antagonizes the effect of Тз at the molecular level. J Endocrinol Invest 1998- 21 :93
- Bogazzi F, Bartalena L, Brogioni S. Color flow doppler sonography rapidly differentiates type I and type II amiodarone-induced thyrotoxicosis. Thyroid 1997 — 7:541−545
- Bogazzi F, Bartalena L, Martino E. Color flow doppler sonography of the thyroid. In: Baskin HJ (ed) Thyroid Ultrasound and Ultrasound-Guided FNA Biopsy. Kluwer Academic Publisher, Boston, 2000- 215−238
- Bogazzi F., Bartalena L. Thyroid various effects of amiodarone on thyroid function Thyroid 2001- 11:5,2001
- Borowski G.D., Garofano C.D., Rose L.I. Effect of long-term amiodarone therapy on thyroid hormone levels and thyroid function. Am J Med 1985- 78: 443−450
- Bosch, R Gaspo, S Nattel. Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes J Pharmacol andExpTher 1999- 289(1): 156−165
- Braverman L.E., Ingbar S.H., Vagenakis A.G. Enhanced susceptibility to iodide myxedema in patients with Hashimoto’s disease. J Clin Endocrinol 1971- 32: 515−521
- Brennan M.D., Erickson D.Z., Carney J.A. Nongoitrous amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo. Thyroid 1995−5:177−183
- Brennan M.D., van Heerden J.A., Carney J.A. Amiodarone-associated thyrotoxicosis (AAT): experience with surgical management. Surgery 1987−102:1062−1067
- Burger A., Dinichert D., Nico D. Effect amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin and thyrotropin J Clin Invest 58: 255- 258, 1986
- Cairns J.A., Connolly S.J., Roberts R. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarization’s: CAMIAT. Lancet, 1997- 349: 675−682.
- Canada A.T., Lesdo L.J., Haffajee C.I. Disposition of amiodarone in patients with tachyarrhythmias. CurrTherRes 1981−30:968−974
- Charlier R., Deltour G., Baudine A. Pharmacology of amiodarone, an antianginal drug with a new biological profile. Arzneim Forsch 1968−18:1408
- Charlier R., Deltour G., Tondeur R. Recherche dans la serie des benzofurannes. VII. Etude pharmacologique preliminaire du butyl-2 (diiodo 3' 5'-beta-N-die&ylamino-ethoxy-4'benzoyl)-3 benzofurannes. Arch Int Pharmacodyn 1962−139:255
- Chiovato L, Martino E, Tonacchera M. Studies on the in vitro cytotoxic effect of amiodarone Endocrinology. 1994 May- 134(5):2277−82.
- Chiovato L., Martino E., Tonacchera M., Santini F., Lapi P., Mammoli C., Braverman L.E., Pinchera A. Studies on the in vitro cytotoxic effect of amiodarone. Endocrinology 1994−134:2277−2282
- Connolly S.J. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999- 100: 2025−2034
- Conolly S.J., Gupta R.N., Hoffert D. Concentration response relationship of amiodarone and desethylamiodarone. Am Heart J 1988- 115: 1208−1213
- Cushing G. W. Subclinical hypothyroidism. Understanding is the key to decision making. Postgrad Med. 1993- 1: 95 97.
- DiCarlo L.A., Morady F., de Buitleir M. Effects of chronic amiodarone therapy on ventricular tachycardia induced by programmed ventricular stimulation. Am Heart J 1987- 113:57−64
- Disatnik M.H., Shainberg A. Regulation of beta-adrenoceptors by thyroid hormone and amiodarone in rat myocardiac cells in culture. Biochem Pharmacol 1991−41:1039−1044
- Dohan 0., de la Vieja A., Paroder V. The Sodium/Iodide Symporter (NIS): Characterization, Regulation, and Medical Significance Endocr. Rev 2003- 24(1): 48−77.
- Doval H., Null D. Randomized trial of low-dose amiodarone in severe heart failure. Lancet 1994- 344: 493−498
- Duane PG, Rice KL, Charboneau DE. Amiodaronc-induccd endothelial injury is associated with phospholipase C-mediated hydrolysis of membrane phospholipids. J Lab Clin Med. 1992 Dec-120(6):955−63
- Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. The Cardiac Arrhythmia Suppression Trial II Investigators. N Engl J Med. 1992- -327(4):227−33
- Faire J., Romero J., Rubio J.M. Amiodarone and «primary» prevention of sudden death: critical review of a decade of clinical trials/ Am J Cardiol 1999- 83: 55D-63D
- Farwell AP, Abend SL, Huang SKS. Thyroidectomy for amiodarone induced thyrotoxicosis. JAMA 1990 263:1526−1528
- Figge J., Dluhy R.G. Amiodarone-induced elevation of thyroid stimulating hormone in patients receiving levothyroxine for primary hypothyroidism. Ann Intern Med 1990- 113: 553−555
- Flanagan R., Storey G., Holt D. Identification and measurement of desethylamiodarone in blood plasma specimens from amiodarone-treated patients. J Pharm Pharmacol 1982- 34: 638
- Folder J. Risk/benefit of thyroid hormone treatment in subclinical hypothyroidism. Thyroid tissues: Merck European Thyroid Symposium, Strasburg, February 3−5, 1994 Schatauer, Stuttgart, 1994- 201−213
- Foresti V., Pepe R., Parisio E. Antithyroid antibodies during amiodarone treatment. Acta Endocrinol 1989- 121: 203−206
- Franklyn J.A., Davis J.R., Gammage M.D. Amiodarone and thyroid hormone function.' Clin Endocrinol 1985−22:257−264
- Hilleman D., Miller M. Optimal management of amiodarone therapy: efficacy and side effects Pharmacotherapy 1998 Nov-Dec, 18:138−145
- Franklyn JA, Daykin J, Betteridge J. Thyroxine replacement therapy and circulating lipid concentrations. Clin Endocrinol (Oxf) 1993- 38: 453−459
- Fredlund, В. O., S. B. Olsson. Long Q-T interval and ventricular tachycardia of «torsade de pointe» type in hypothyroidism. Acta Med. Scand. 1993- 213: 231−235.
- Friedman M., Byers S.O., Rosenman N.H. Changes in excretion of intestinal cholesterol and sterol digitonides in hypo- and hyperthyroidism. Circulation 1952- 5:657
- Graboys T.B., Lown В., Podrid P.J. Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. Am J Cardiol 1982- 50:437−447
- Gross, SA, Bandyopadhyay S, Klanning JE. Amiodarone and desethylamiodarone toxicity in isolated hepatocytes in culture. Proc Soc Exp Biol Med 190: 163−170,1989
- Hack A.E., Pols H.A., Visser T.J. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women- the Rotterdam Study Ann Intern Med 2000- 132: 4: 270
- Hamer A.W.F., Mandel W.L., Zaher C.A. The electrophysiologic basis for the use of amiodarone for the treatment of cardiac arrhythmias. Pacin Clin Electriphysiol 1983- 6: 784−794
- Haqai K.J., Licata A.A. Amiodarone-induced hyperthyroidism: a case series and brief review of literature. Pacing Clin Electrophysiol 1996- 19:1548−1554
- Haijai K.J., Licata A.A. Effects of amiodarone on thyroid function. Ann Intern Med 1997−126:63−73
- Hawthorne G.C., Campbell N.P.S., Geddes J.S. Amiodarone-induced hypothyroidism: a common complication of prolonged therapy. A report of eight cases. Arch Intern Med 1985- 145: 1016−1019
- Hawthorne G.C., Campbell N.P.S., Geddes J.S. Amiodarone-induced hypothyroidism: a common complication of prolonged therapy. A report of eight cases. Arch Intern Med 1985- 145: 1016−1019
- Hazzard W.R., Bierman E.L. Aggravation of broad beta disease type 3 hyperlipoproteinemia by hypothyroidism. Arch Intern Med 1972- 130:822
- Heimberg M, Olubadewo JO, Wilcox HG. Plasma lipoproteins and regulation of hepatic metabolism of fatty acids in altered thyroid states. Endocr Rev 1985 6:590−607
- Hersliman J.M., Nademanee K., Sugawara M. Thyroxine and triiodothyronine kinetics in cardiac patients taking amiodarone. Acta Endocrinol 1986−111:193−199
- Holt D.W., Tucker G.T., Jackson P.R. Amiodarone pharmacokinetics. Am Heart J 1983- 106: 840−847
- Hoogerbrugge N., Jansen H., Staels B. Growth hormone normalizes low-density lipoprotein receptor gene expression in hypothyroid rats. Metabolism 1996- 45: 680
- Iudica-Souza C., Burch H.B. Amiodarone-induced thyroid dysfunction. The Endocrinologist 1999−9:216−227
- Jonckheer M.H. Amiodarone and the thyroid gland: a review. Acta Cardiol 1981- 36: 199−205
- Kannan R., Miller S., Singh B.N. A sensitive HPLC method for the measurement of amiodarone and desethylamiodarone in serum and tissues and its application to disposition studies. J Chromatog 1987- 385:225
- Kannan R., Nademanee K., Hendrickson J. Amiodarone kinetics after oral doses. Clin Pharmacol Ther 1982- 31: 438−444
- Keating F.R. Jr, Parking T.W., Selby J.B. Treatment of heart disease associated with myxedema. Prog Cardiovasc Dis 1961−3:364−381
- Keh-Chuan Loh Amiodarone-induced thyroid disorders: a clinical review Postgrad Med J 2000−76:133−140
- Kerin N.Z., Blevins R.D., Benaderet D. Relation of serum reverse T3 to amiodarone antiarrhythmic efficacy and toxicity. Am J Cardiol 1986- 57:128
- Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001- 344: 501−509
- Klein I, Ojamaa K. Thyroid hormone: targeting the heart. Endocrinology. 2001- 142: 11−12.
- Kung AW, Pang RW, Lauder I Changes in serum lipoprotein (a) and lipids during treatment of hyperthyroidism. Clin Chem 1995- 41:226−231
- Kutty K. M, Biyant D.G., Farid N.R. Serum lipids in hypothyroidism ~ a reevaluation. J Clin Endocrinol Metab 1978- 46: 55−56
- Ladenson P.W., Meinert C.L., Powe N.R. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000- 85:2993
- Lambert C, Halpert JR, Rouleau J. Effect of congestive heart failure on the intrinsic metabolic capacity of the liver in the dog. Drug Metab Dispos. 1991−19(5):985−9
- Lee J.-K., Hayashi Y., Miwa K. Genomic Induction of cardiac hypothyroidism: a novel approach to prevent life-threatening arrhythmias AHA 2001, Abstracts on disc 159
- Levine H.D. Compromise therapy in patients with angina pectoris and hypothyroidism: a clinical assessment Am J Med 1980- 69: 411−418
- Lithel H., Boberg J., Hellsing K. Serum lipoprotein and apolipoprotein concentration and tissue lipoprotein lipase activity in overt and subclinical hypothyroidism: the effects of substitution therapy. Eur J Clin Invest 1981- 11:3
- Liu P, Fei L, Wu W. Effects of hypothyroidism on the vulnerability to ventricular fibrillation in dogs: A comparative study with amiodarone. Cardiovasc Drugs Ther 1996- 10: 369−378
- Lombardi A., Martino E., Braverman L.E. Amiodarone and the thyroid. Thyroid Today 1990−13:1−7
- Loviselli A., Bartalena L., Balzano S. Absence of serum thyroid hormone autoantibodies in patients chronically treated with amiodarone. J Endocrinol Invest 1988- 11: 323−325
- Mahmarian J.J., Smart E.W., Moye L.E. Exploring the minimal dose of amiodarone with antiarrhythmic and hemodinamic activity. Am J Cardiol 1994- 74: 681−686
- Manninen V., Elo M.O., Frick M.H. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988- 260: 641−651
- Mariotti S., Loviselli A., Murenu S. High prevalence of thyroid dysfunction in adult patients with B-thalassemia major submitted to amiodarone treatment. J Endocrinol Invest 1999−22:55−63
- Martino E, Aghini-Lombardi F, Lippi F. Twenty-four hour radioactive iodine uptake in 35 patients with amiodarone associated thyrotoxicosis. JNucl Med 1985- 26:1402−1407
- Martino E, Aghini-Lombardi F, Mariotti S. Treatment of amiodarone associated thyrotoxicosis by simultaneous administration of potassium perchlorate and methimazole. J Endocrinol Invest 1986- 9:201−207
- Martino E, Bartalena L, Mariotti S. Radioactive iodine uptake in patients with amiodarone-iodine-induced thyroid dysfunction. Acta Endocrinol (Copenh) 1988- 119:167−173
- Martino E, Macchia E, Aghini-Lombardi F. Is humoral thyroid autoimmunity relevant in amiodarone iodine-induced thyrotoxicosis (AIIT)? Clin Endocrinol (Oxf) 1986- 24: 627−633
- Martino E., Aghini-Lombardi F., Mariotti S. Amiodarone: a common source of iodine-induced thyrotoxicosis. HormRes 1987- 26:158−171
- Martino E., Aghini-Lombardi F., Mariotti S. Amiodarone iodine-induced hypothyroidism: risk factors and follow-up in 28 cases. Clin Endocrinol 1987- 26: 227−237
- Martino E., Safran M, Aghini-Lombardi F. Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. Ann Intern Med 1984−101:28−34
- Massie В., Fisher S., Radford M. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation 1996- 93: 21 282 134
- Meier С, Staub J.J., Roth C.B. TSH-Controlled L- in Subclinical Hypothyroidism: A Double Blind, Placebo-Controlled Trial (Thyroxine Therapy Reduces Cholesterol Levels and Clinical Symptoms Basel Thyroid Study)
- Meurisse M., Hamoir E., D’Silva M. Amiodarone-induced thyrotoxicosis: is there a place for surgery? World J Surg 1993−17:622−627
- Middlekauf H.R. Weiner I. Stevenson W.G. Low-dose Amiodarone for atrial fibrillation Am J Cardiol 1993- 72:75F-81F
- Mitcell L.B., Wyse G., Gillis A.M. Electropharmacology of amiodarone therapy initiation. Circulation 1989- 80: 34−42
- Monteiro E, Galvao-Teles, Santos M.L. Antithyroid antibodies as an early marker for thyroid disease induced by amiodarone. Br Med J Clinical Research Edition 1986- 292: 227−228
- Newman C.M., Price A., Davies D.W. Amiodarone and the thyroid: a practical guide to the management of thyroid. Postgard Med J 2001- 66:123−150
- Newnham H.H., Topliss D.J., Le Grand B.A. Amiodarone-induced hyperthyroidism: assessment of the predictive value of biochemical testing and response to combined therapy with propylthiouracil and potassium perchlorate. Aust NZ J Med 1988−18:37−44
- Nikkila E., Kekki M. Plasma triglyceride metabolism in thyroid disease. J Clin Invest 1973−51:73
- O’Brien Т., Dinneen S.F. Hyperlipidemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993- 68: 860
- Ohyama K., Nakajima M., Suzuki M. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. J Clin Pharmacol 2000- 49- 244−253
- Pearce E.N., Lewis F. Subclinical hyperthyroidism. Thyroid Intern 2001- 5
- Peters, A., Ehlers, M., Blank, B. Excess Triiodothyronine as a Risk Factor of Coronary Events. Arch Intern Med 2000- 160: 1993−1999
- Pitsivas V., Smerdely P., Boyages S.C. Amiodarone induces a different pattern of ultrastructural change in the thyroid to iodine excess alone in the both the BB/W rat and the Wistarrat Eur J Endocrinol 1997−137:89−98
- Ponte E., Ursu H.I. Overt and subclinical hypothyroidism and atherosclerotic arteriopathy of the lower limbs (clinical and subclinical) Rom J Endocrinol 1993- 31: P. 71 79
- Priori S.G., Aliot E., Blomstrom-Lundqvist C. Task force on sudden cardiac death of the European society of cardiology. Eur Heart J 2001- 22, 1374−1450.
- Rabinowe S.L., Larsen P.R., Antman E.M. Amiodarone therapy and autoimmune thyroid disease. Increase in a new monoclonal antibody-defined T cell subset. Am J Med 1986−81:53−57
- Rao R. IL, McReady V.R., Spathis G.S. Iodine kinetic studies during amiodarone treatment. J Clin Endocrinol Metab 1986- 62: 563−567
- Rappersberger K., Hanigsmann H. Photosensitivity and hyperpigmentation in amiodarone treated patients: incidence, time course and recovery J Invest Dermatol 1989 Aug- 93(2):201−9
- Reichert LJM, de Rooy H. A.M. Treatment of amiodarone induced hyperthyroidism with potassium perchlorate and methimazole during amiodarone treatment. Br Med J 1989- 298:1547−1548
- Ritter M.C., Kannan C.R., Bagdade J.D. The effects of hypothyroidism and replacement therapy on cholesterol ester transfer. J Clin Endocrinol Metab 1996- 81: 797
- Safran M., Martino E., Aghini-Lombardi F. Effect of amiodarone on circulating antithyroid antibodies. Br Med J 1988- 297: 456−457
- Sanmarti A., Permanyer-Miralda G. Chronic administration of amiodarone and thyroid function: a follow-up study. Am Heart J 1984- 108: 1262−1268
- Sato K, Yamazaki K, Kanaji Y. Amiodarone-induced thyrotoxicosis associated with thyrotropin receptor antibody. Thyroid 1998- 8:1123−1126
- Shiga Т., Wakaumi M., Shoda M. Amiodarone-induced dysfunction and ventricular tachyarrhythmias during long term therapy in Japan. Jpn Circ J 2001- 65: 958−960.
- Singer P.A., Cooper D.S., Levy E.G. Treatment guidelines for patients with hyper- and hypothyroidism. Standards of Care Committee, American Thyroid Association JAMA 1995- 273: 808−812
- Singh B. Control of cardiac arrhythmias by lengthing repolarisation- 1988, Futura Publishing Company, Inc.
- Singh В., Jewitt D., Downey J. Effects of amiodarone and L8040, novel antianginal and antiarrhythmic drugs, on cardiac and coronary hemodynamics and on cardiac intracellular potentials. Clin Exp Pharmacol Physiol 1976- 3:426
- Singh B.N. Amiodarone: historical development and pharmacologic profile. Am Heart J 1983- 106: 788−797.
- Singh B.N., Vaugham Williams E.M. The effect of amiodarone, a new anti-anginal drug, on cardiac muscle. Br J Pharmacol 10 970- 39: 657−667
- Singh S., Fletcher R., Fisher S. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995- 333: 77−82
- Smyrk T.C., Goellner J.R., Brennan M.D. Pathology of the thyroid in amiodarone-associated thyrotoxicosis. Am J Surg Pathol
- Sogol P.P., Hershman J.M., Rees A.W. The effects of amiodarone on serum thyroid hormones and hepatic 5'-deiodinase. Endocrinology 1983- 113:1464−1469
- Staubli M, Studer H Amiodarone-treated patients with suppressed TSH test are at risk of thyrotoxicosis. Klin Wochenschr 1985- 63:168−175
- Staubli M., Bircher J, Galeazzi RL. Serum concentrations of amiodarone during long term therapy: relation of dose, efficacy and toxicity. Eur Clin Pharmacol 24- 485,1983
- Storey C.G.A., Holt D.W., Holt P. High perfomance liquid hromatographic measurement of amiodarone and its desethyl metabolite: methodology and preliminary observation. Therapeut Drug Monitoring 1983
- Sun Z-Q, Ojamaa K, Coetzee WA. Effects of thyroid hormone on action potential and repolarizing currents in rat ventricular myocytes. Am J Physiol. 2000−278:E3022-E3027.
- Talajic, M., S. Nattel, M. Davies. Attenuation of class 1П and sinus node effects of amiodarone by experimental hypothyroidism J. Cardiovasc. Pharmacol. 1989−13: 447−450.
- Tanis ВС, Westendorp RGJ, Smelt AHM. Effect of thyroid substitution on hypercholesterolaemia in patients with subclinical hypothyroidism: a reanalysis of intervention studies. Clin Endocrinol (Oxf) 1996- 44:643−649
- The Cardiac Arrhythmia Suppression Trial (CAST) investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989- 321:406−412
- The CASCADE investigators. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest. AM J Cardiol, 1993- 72:280−287
- Thompson G.R. What targets should lipid-lowering therapy achieve to optimize the prevention of coronary heart disease? Atherosclerosis 1997- 131:1−5
- Thorne SA, Barnes I, Cullinan P. Amiodarone-associated thyroid dysfunction. Risk factors in adults with congenital heart disease. Circulation 1999- 149−154
- Tieche M., Lupi G.A., Gutzwiller F. Borderline low thyroid function and thyroid autoimmunity. Risk factors for coronary artery disease? Br Heart J 1981- 46: 202
- Tisdale J., Fallin S. «Risk factors for the development of special noncardiovascular adverse effects associated with amiodarone» J Clin Pharmacol 1995 Apr- 35(4):351−6
- Torres V. QT prolongation and the antiarrhythmic efficacy of amiodarone. J Am Coll Cardiol. 1986−7(1): 142−7.
- Touboul P. A decade of clinical trials: CAST to AVID. Eur Heart J 1999, C2-C10
- Trip M.D. Wiersinga W.M., Plomp T.A. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am J Med 1991- 1: 507−511 Trotter WR The relative toxicity of antithyroid drugs. J New Drugs 1962- 2:333−343
- Vagenakis A. G, Downs P., Braverman L.E. Control of thyroid hormone secretion in normal subjects receiving iodides. J Clin Invest 1973−52:528−532
- Vandergheyust F., Lirnart F. Amiodarone et dysthyroidies etude prospective et revue de la litteratura. Rev Med Brux 1999 Oct- 20(5):411−7
- Vaugham Williams E.M. Classification of antiarrhythmic drugs. In: Symposium of on cardiac arrhythmias. E. Sandoe et al. Sodertajie (Sweden), AB Astra, 1970- 440:449
- Venkatesh N., Lynch J., Uprichard A.C. Hypothyroidism renders protection against lethal ventricular arrhythmias in a conscious canine model of sudden death. J Cardiovasc Phamiacol 1991−18(5):703−10
- Venkatesh N., Lynch J.J., Uprichard A.C. Hypothyroidism renders protection against lethal ventricular arrhythmias in a conscious canine model of sudden death. J Cardiovasc Pharmacol 1991- 18(5):703−10
- Venkatesh N., Somani P., Bersohn M. Electropharmacology of amiodarone: absence of relationship to serum, myocardial and cardiac sarcolemmal membrane drug concentration. Am Heart J 112:5,916,1986
- Verdugo C, Perrot L, Ponsin G. Time-course of alterations of high density lipoproteins (HDL) during thyroxine administration to hypothyroid women. Eur J Clin Invest 1987- 17:313−316
- Visual functions and adverse effectsin patients with amiodarone medication Acta Ophtalmol Scand 2002 Feb- 80: 59−63
- Weetman A.P., Bhandal S.K., Burrin J.M. Amiodarone and thyroid autoimmunity in the United Kingdom. Br Med J 1988- 297: 33−36
- Weintraub M, Grosskopf I, Trostanesky Y. Thyroxine replacement therapy enhances clearance of chylomicron remnants in patients with hypothyroidism. J Clin Endocrinol Metab. 1999- 84:2532−2536
- Wenzel KW, Lente JR. Similar effects of thionamide drugs and perchlorate on thyroid stimulating immunoglobulins in Graves' disease: evidence against immunosuppressive action of thionamide drugs. J Clin Endocrinol Metab 1984- 58:62−69
- Wiersinga W.M., Trip M.D. Amiodarone and thyroid hormone metabolism. Postgrad Med J 1986- 62:909−914
- Wiersinga WM Amiodarone and the thyroid. In: Weetman AP, Grossman A Pharmacotherapeutics of the Thyroid Gland. Springer Verlag, Berlin, 1997- 225−287
- Wimpfheimer C, Staubli M, Schadelin J. Prednisone in amiodarone-induced thyrotoxicosis. Br Med J 1982- 284:1835−1836
- Woeber KA. Thyrotoxicosis and the heart. N Engl J Med 1992−327:94−98.
- Wolff J. Iodide goiter and the pharmacologic «effects of excess iodide. Am J Med 1969−47:101−105
- Wolff J. Perchlorate and the thyroid gland. Pharmacol Rev 1998- 50: 89−105
- Wolff J., Chaikoff I.L., Goldberg R.C. The temporary nature of the inhibition action of excess iodide on organic iodine synthesis in the normal thyroid. Endocrinology 1949- 45: 504−513
- Wood D., Backer G.D., Faergeman O. Prevention of coronaiy heart disease in clinical practice: Recommendation of the Second Joint Task Force of European and other Societies of Coronary Prevention. Atherosclerosis 1998- 140:199−270
- Yasuda SU, Sausville EA, Hutchins JB. Amiodarone-induced lymphocyte toxicity and mitochondrial function. J Cardiovasc Pharmacol. 1996 Jul-28(l):94−100.
- Zipes D.P., Prystowsky E.N., Heger J.J. Amiodarone: Electrophysiologic actions, pharmacokinetics and clinical effects. J Amer Coll Cardiol 3:1059−1062, 1984
- Chatelian P., Laruel R. Amiodarone partitioning with phospholipid bilayers and erythrocyte membranes. J Pharm Sci 1985- 74: 783−784